Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 11, 2020
Previous Article Next Article

Discovery of new polycyclic polyprenylated acylphloroglucinols with diverse architectures as potent cyclooxygenase-2 inhibitors

Author affiliations

Abstract

Cyclooxygenase-2 (COX-2) is a significant therapeutic target of chronic inflammatory diseases. Soniiglucinols A–D (1–4), four new polycyclic polyprenylated acylphloroglucinols (PPAPs) with diverse architectures, were isolated from Hypericum wilsonii. Structurally, 1 and 2 represent the first examples of PPAPs that are uniquely defined by the presence of a fascinating tricyclo-[7.3.1.03,7]tridecane core bearing an unusual 5/7/6 carbon skeleton. Compounds 3 and 4 were the first PPAPs sharing intriguing tricyclo-[7.3.1.02,7]tridecane and tricyclo-[6.3.1.02,6]dodecane moieties, respectively. More significantly, 1 and 2 were the first reported PPAPs functioning as potent cyclooxygenase-2 (COX-2) inhibitors with efficient anti-inflammatory activities, which provided a basis to design novel COX-2 inhibitors based on the new tricyclo-[7.3.1.03,7]tridecane fragment.

Graphical abstract: Discovery of new polycyclic polyprenylated acylphloroglucinols with diverse architectures as potent cyclooxygenase-2 inhibitors

Back to tab navigation

Supplementary files

Article information


Submitted
27 Feb 2020
Accepted
15 Apr 2020
First published
16 Apr 2020

Org. Chem. Front., 2020,7, 1349-1357
Article type
Research Article

Discovery of new polycyclic polyprenylated acylphloroglucinols with diverse architectures as potent cyclooxygenase-2 inhibitors

S. Xie, C. Qi, Y. Duan, Q. Xu, Y. Liu, Y. Huang, X. Yin, W. Sun, Y. Zhou and Y. Zhang, Org. Chem. Front., 2020, 7, 1349
DOI: 10.1039/D0QO00259C

Social activity

Search articles by author

Spotlight

Advertisements